December 19, 2025 — Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) is in the spotlight today after announcing additional financing tied to its planned Bluejay Therapeutics acquisition and drawing bullish analyst commentary that helped power a sharp move in the stock.
As of the latest reported trade on Friday, December 19, 2025, MIRM was trading around $76.71, up about 9.15% from the prior close, after touching an intraday high near $77.19.
What’s driving Mirum Pharmaceuticals stock today
Two catalysts are dominating the narrative on 19.12.2025:
- Mirum announced an additional private placement with TCGX (a PIPE-style financing) designed to close alongside the Bluejay acquisition.
- A key analyst note (Citizens) raised its price target to $140, reinforcing the idea that the market is re-rating Mirum based on “multiple shots on goal” across rare liver disease and now hepatitis delta virus (HDV). Investing.com India+1
That combination—fresh capital + pipeline-driven upgrade energy—is the kind of fuel that can move a mid-cap biotech fast, especially when investors are already paying attention to an upcoming acquisition.
Today’s headline: Mirum’s new $68.5M private placement with TCGX
Mirum disclosed it has entered into a subscription agreement with entities associated with TCGX for the private placement of 1,000,000 shares priced at $68.48 per share, for approximately $68.5 million in gross proceeds.
A few details matter for stock investors:
- Timing: The financing is structured to purchase shares immediately following the closing of Mirum’s previously announced mergers connected to the Bluejay transaction, which Mirum expects to close in Q1 2026 (subject to conditions).
- Registration rights: Mirum also entered into a registration rights agreement and committed to filing a resale registration statement for these shares after closing.
- Non-registered offering: The shares will be sold in a private placement not registered under the Securities Act (relying on an exemption), which is standard for PIPE-style deals.
Why this financing matters (and why dilution is part of the conversation)
The bullish interpretation: Mirum is funding a larger strategic swing—expanding beyond its current rare cholestatic disease franchise into an HDV program with late-stage aspirations—without waiting for public market windows to cooperate.
The cautious interpretation: private placements add shares (or share-linked securities) that can be dilutive, and the closing is contingent on the Bluejay transaction completing.
The bigger backdrop: Bluejay acquisition and the earlier $200M private placement
Today’s $68.5M placement is explicitly positioned as an “add-on” to a separately announced $200M private placement that Mirum tied to the same Bluejay deal earlier this month. SEC+1
Mirum’s Bluejay plan (as disclosed in company statements and filings) includes:
- Upfront consideration:$250M in cash plus up to 5,196,009 shares of Mirum stock (described as ~$370M based on a defined VWAP calculation), plus up to $200M in sales-based milestone payments.
- Expected close:First quarter of 2026, subject to customary conditions (including regulatory/HSR timing).
- Strategic asset: Bluejay’s brelovitug, a monoclonal antibody being evaluated in a Phase 3 registrational program for chronic hepatitis delta virus (HDV), with topline results expected in 2H 2026.
How the $200M raise was structured
In Mirum’s December 6, 2025 Form 8-K, the company described a roughly $200M private placement involving:
- 2,385,149 shares of common stock, plus
- pre-funded warrants for 536,412 shares,
priced around $68.48 (and $68.4799 for pre-funded warrants, reflecting the minimal exercise price structure).
In other words: today’s $68.5M is not the first financing linked to this acquisition—it’s an additional layer.
Analyst forecasts and price targets: why $140 hit the tape today
On December 19, multiple market summaries pointed to Citizens raising its price target to $140 (from $95) while maintaining a positive rating.
One Investing.com report said the firm cited confidence in upcoming pivotal readouts, including the newly acquired brelovitug program and Mirum’s existing liver pipeline, and discussed probability-of-success assumptions and peak sales estimates as part of its rationale.
What “consensus” looks like (and why it varies by data source)
Depending on the data provider, the consensus target and rating differ—because analyst universes, update timing, and data normalization differ. Here are three widely referenced snapshots circulating today:
- StockAnalysis: 11 analysts, consensus “Strong Buy,” average target $92.45, with a low of $72 and a high of $140. StockAnalysis
- TradingView (FactSet-sourced reference data): price target shown at $98.60, with a max estimate $140 and min estimate $81.
- MarketBeat: consensus target shown around $100.25, with a mix of Buy/Strong Buy ratings and one Sell (as summarized in its update).
The takeaway isn’t that one number is magically “correct.” It’s that the Street is largely aligned on a core thesis: Mirum is no longer “just” a Livmarli story—it’s a broader rare liver + HDV pipeline platform that could justify a higher multiple if the next wave of data cooperates.
Fundamentals: Mirum’s revenue base is growing, and guidance is already in play
This isn’t a pre-revenue biotech trying to will itself into existence. Mirum has a commercial portfolio, led by:
- LIVMARLI (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC)
- bile-acid medicines including CHOLBAM and CTEXLI (chenodiol)
In its Q3 2025 update, Mirum reported:
- Total revenue / global net product sales:$133.0M
- LIVMARLI net product sales:$92.2M (56% growth year-over-year)
- Bile Acid Medicines net product sales:$40.8M (31% growth year-over-year)
- Full-year 2025 revenue guidance:$500M–$510M
That guidance range is showing up in analyst commentary as a baseline for valuation discussions going into 2026.
Pipeline catalysts: what investors are actually betting on
Mirum’s stock doesn’t move like a slow-and-steady dividend payer. It trades like a biotech with event gravity—where a few future dates matter more than a thousand past ones.
Key upcoming catalyst windows frequently cited in company updates and filings include:
1) Volixibat (IBAT inhibitor) — pivotal data in 2026
Mirum has highlighted volixibat in liver diseases including primary sclerosing cholangitis (PSC). The company has stated that its VISTAS study enrollment was complete, with topline data expected in Q2 2026.
2) Brelovitug (via Bluejay) — Phase 3 topline in 2H 2026
Brelovitug is being evaluated in the AZURE Phase 3 registrational program for HDV, with topline results expected in 2H 2026, and the company has discussed a potential pathway toward BLA submission/launch timing if successful.
3) MRM-3379 (PDE4D inhibitor) — Fragile X Phase 2 underway
Mirum announced the first patient enrolled in BLOOM, a Phase 2 study evaluating MRM-3379 in Fragile X syndrome, emphasizing there are currently no approved therapies for Fragile X and positioning this program as another “option value” driver longer term. Business Wire+1
Risks and reality checks (because biology doesn’t care about your price target)
Even with bullish ratings, Mirum’s story has real risk vectors investors should keep in view:
- Execution and integration risk: Closing the Bluejay transaction (and integrating the program) is not automatic; filings describe conditions and timelines, and deals can slip.
- Clinical risk: Late-stage trials can disappoint. The HDV thesis depends heavily on Phase 3 performance, and volixibat has important readouts ahead.
- Financing/dilution mechanics: Multiple private placements plus stock consideration for M&A can increase the share count and pressure per-share valuation if outcomes don’t justify it.
- Profitability timing: Analysts and market commentary still flag that Mirum is not necessarily expected to be profitable in the near term, even as revenue grows.
Bottom line: Mirum stock is being repriced as a broader rare liver platform
On December 19, 2025, Mirum Pharmaceuticals stock is moving on a clean narrative: raise capital, expand the pipeline, and win incremental confidence from Wall Street.
The near-term market question isn’t whether Mirum can sell Livmarli—it’s whether the company can successfully close the Bluejay deal and convert a stacked catalyst calendar (volixibat + HDV + Fragile X optionality) into durable value that justifies the higher targets now circulating.
